(ADAP) - Earnings & Price History

ADAP: - 7.57, $0.00M, -0.28 (-3.57%)

Sector: Healthcare - Industry: Biotechnology

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companys lead program includes NY-ESO cancer antigen, which is in Phase 1/2 clinical trials for the treatment of patients with solid tumors, as well as hematological cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune Therapeutics plc is also developing MAGE A-10 TCR that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and other solid tumors; and Alpha Fetoprotein TCR therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma

Past ADAP reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-13BMO-0.274.894.615.344.575.6515.84%-8.43%6.07%1.10M
2016-11-10-0.285.015.024.984.785.09-0.80%▲0.60%-0.20%147.33K
2016-08-08-0.268.087.857.797.788.1-0.76%3.72%2.93%168.28K
2016-05-12-0.198.48.258.198.18.6-0.73%2.56%1.82%54.26K
2016-03-17-0.147.617.537.517.417.79-0.27%1.33%1.06%107.70K
2015-11-13

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades